Merck Aktie
WKN DE: A0YD8Q / ISIN: US58933Y1055
22.08.2024 14:17:01
|
Health Canada Approves Keytruda-Padcev Combo For Certain Patients With Urothelial Cancer
(RTTNews) - Thursday, Merck & Co., Inc. (MRK) announced that Health Canada has approved its blockbuster cancer drug Keytruda for yet another indication.
Keytruda in combination with antibody-drug conjugate Padcev (enfortumab vedotin) has been approved for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC.
The approval was based on results from the phase III KEYNOTE-A39 trial, in which the combination of KEYTRUDA and enfortumab vedotin demonstrated statistically significant improvements in overall survival (OS) and progression-free survival (PFS) compared to platinum-based chemotherapy.
Keytruda received its first approval in Canada in 2015. The drug is approved for a number of indications including advanced renal cell carcinoma, bladder cancer, non-small cell lung carcinoma, primary mediastinal B-cell lymphoma, classical Hodgkin lymphoma, colorectal cancer, endometrial carcinoma, cervical cancer, esophageal cancer, triple-negative breast cancer, melanoma, and head and neck squamous cell carcinoma.
In pre-market activity on the NYSE, the shares are trading at $116.20, up 0.15%.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Merck Co.mehr Nachrichten
25.04.25 |
Aufschläge in New York: Dow Jones letztendlich freundlich (finanzen.at) | |
25.04.25 |
Zurückhaltung in New York: So steht der Dow Jones am Nachmittag (finanzen.at) | |
25.04.25 |
NYSE-Handel Dow Jones fällt (finanzen.at) | |
25.04.25 |
Minuszeichen in New York: Dow Jones zum Start des Freitagshandels in der Verlustzone (finanzen.at) | |
24.04.25 |
NYSE-Handel: Dow Jones schlussendlich mit grünen Vorzeichen (finanzen.at) | |
24.04.25 |
Optimismus in New York: Dow Jones präsentiert sich fester (finanzen.at) | |
24.04.25 |
Gute Stimmung in New York: Dow Jones am Donnerstagmittag mit Gewinnen (finanzen.at) | |
24.04.25 |
Gewinne in New York: Dow Jones beginnt Donnerstagshandel im Plus (finanzen.at) |
Analysen zu Merck Co.mehr Analysen
Aktien in diesem Artikel
Merck Co. | 72,70 | 4,30% |
|